Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

NEXT STORY
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
PREV STORY
Infection Control Market Worth $58 billion by 2027, Growing at a CAGR of 13.3% From 2020, Says Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe

NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...

author_avatar
NASDAQ Market News

Biopharmaceutical Market Scope Rising With Escalating Health Concerns – IndustryARC

Hyderabad, India, March 27, 2017 (GLOBE NEWSWIRE) -- The report “Biopharmaceutical Market: By Source ...

author_avatar
NASDAQ Market News

Stemline Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

author_avatar
NASDAQ Market News